Browsing by Author "Aksoy, Sercan"
Now showing items 1-7 of 7
-
The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors
Guven, Deniz Can; Aktepe, Oktay Halit; Aksun, Melek Seren; Sahin , Taha Koray; Kavgaci, Gozde; Ucgul, Enes; Cakir, Ibrahim Yahya; Yildirim, Hasan Cagri; Guner, Gurkan; Akin, Serkan; Kertmen, Neyran; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Suayib, Yalcin; Kilickap, Saadettin (IOS Press, 2022)BACKGROUND: The albumin-globulin ratio (AGR) could be a prognostic biomarker in patients with cancer, although the data is limited in patients treated with immune-checkpoint inhibitors (ICIs). OBJECTIVES: We aimed to ... -
The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Guven, Deniz Can; Sahin, Taha Koray; Erul, Enes; Cakir, Ibrahim Yahya; Ucgul, Enes; Yildirim, Hasan Cagri; Aktepe, Oktay Halit; Erman, Mustafa; Kilickap, Saadettin; Aksoy, Sercan; Yalcin, Suayib (MDPI, 2022)Dynamic changes in the blood-based biomarkers could be used as a prognostic biomarker in patients treated with immune checkpoint inhibitors (ICIs), although the data are limited. We evaluated the association between the ... -
The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A systematic review and meta-analysis
Guven, Deniz Can; Sahin, Taha Koray; Erul, Enes; Kilickap, Saadettin; Gambichler, Thilo; Aksoy, Sercan (PMC, 2022)Background: Prognostic scores derived from the blood count have garnered significant interest as an indirect measure of the inflammatory pressure in cancer. The recently developed pan-immune-inflammation value (PIV), an ... -
The benefit of treatment beyond progression with immune checkpoint inhibitors: A multi-center retrospective cohort study
Guven, Deniz Can; Yekeduz, Emre; Erul, Enes; Coskun Yazgan, Sati; Sahin, Taha Koray; Karatas, Gokturk; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Urun, Yuksel; Kilickap, Saadettin (Springer, 2022)Objective: Treatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional imaging in response evaluation. However, real-life data on the benefit of ... -
Blood based biomarkers as predictive factors for hyperprogressive disease
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aksoy, Sercan; Erman, Mustafa; Kilickap, Saadettin; Yalcin, Suayib (MDPI, 2022)Purpose: With the widespread use of immunotherapy agents, we encounter treatment responses such as hyperprogression disease (HPD) that we have not seen with previous standard chemotherapy and targeted therapies. It is known ... -
Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aktas, Burak Yasin; Guner, Gurkan; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Kilickap, Saadettin (Kare Publishing, 2022)Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter ... -
The frequency and determinants of metabolic syndrome in operated patients with stage ı-ııı breast cancer
Sarici, Furkan; Sunar, Veli; Aksoy, Sercan (Akad Doktorlar Yayinevi, 2020)Metabolic syndrome is a clinical condition with a combination of multiple cardiac risk factors including obesity, insulin resistance, hypertriglyceridemia, low HDL, and hypertension. There is serious evidence that metabolic ...
